News &amp; Updates

The combination of lenvatinib and pembrolizumab improved progression-free survival (PFS) and overall survival (OS) compared with physician’s choice of treatment (TPC) among patients with advanced endometrial cancer with prior exposure to platinum-based therapy, regardless of DNA mismatch repair (MMR) status, according to results of a phase III study presented at IGCS 2021.

Lenvatinib-pembrolizumab improves OS, PFS in advanced endometrial carcinoma regardless of DNA MMR status

Moderna vs Pfizer vax: Is one better against Delta?

While both mRNA vaccines available on the market are strongly protective against SARS-CoV-2 infection and severe COVID-19 illness, emerging real-world data suggest that Moderna’s mRNA-1273 is more effective than Pfizer-BioNTech’s BNT162b2 vaccine in the face of Delta predominance.

Moderna vs Pfizer vax: Is one better against Delta?

PEG placement-related bleeding risk minimal in patients on uninterrupted antithrombotic therapy

Patients on uninterrupted periprocedural antithrombotic therapy have a negligible risk of significant bleeding associated with the placement of a percutaneous endoscopic gastrostomy (PEG) tube, a recent study has shown.

PEG placement-related bleeding risk minimal in patients on uninterrupted antithrombotic therapy

Apalutamide plus ADT effective against pain, fatigue in metastatic prostate cancer

Treatment with apalutamide plus androgen deprivation therapy (ADT) results in consistently favourable pain scores and less interference from pain in the daily lives of patients with metastatic castration-sensitive prostate cancer compared with placebo plus ADT, results of the phase III TITAN study have shown. Moreover, there was no difference for change seen in fatigue with apalutamide vs placebo.

Apalutamide plus ADT effective against pain, fatigue in metastatic prostate cancer

Pembrolizumab may alter adjuvant treatment landscape of kidney cancer

The use of pembrolizumab significantly improved disease-free survival (DFS) in patients with clear-cell renal cell carcinoma (RCC) who have undergone nephrectomy, with or without metastasectomy, and were at high risk for recurrence, according to the phase III KEYNOTE-564 trial.

Pembrolizumab may alter adjuvant treatment landscape of kidney cancer

Multiple regimens of no help in cardiac light chain amyloidosis

Treatment with the bortezomib-cyclophosphamide-dexamethasone (CyBorD) combination plus doxycycline falls short of improving progression-free survival (PFS) or cardiac PFS in patients with light chain amyloidosis, according to the results of a trial.

Multiple regimens of no help in cardiac light chain amyloidosis

Vedolizumab safer than anti-TNFs for older IBD patients

In the treatment of older patients with inflammatory bowel disease (IBD), vedolizumab is linked to a lower risk of infection-related hospitalization compared with antitumour necrosis factor-α (anti-TNF) agents, according to a study.

Vedolizumab safer than anti-TNFs for older IBD patients

Youth-onset T2D linked to long-term complications

15 Sep 2021 by

Patients with youth-onset type 2 diabetes (T2D) are at an increased risk of developing long-term complications, according to follow-up results of the US-based TODAY* study.

Youth-onset T2D linked to long-term complications

Perioperative opioid fill tied to new persistent use in ophthalmic surgery patients

Exposure to opioids in the perioperative period appears to result in new persistent use in patients who were previously opioid-naïve, according to a study, which suggests that exposure to opioids is an independent risk factor for persistent use in those undergoing incisional ophthalmic surgery.

Perioperative opioid fill tied to new persistent use in ophthalmic surgery patients

Pooled ORION analysis boosts lipid-lowering potential of inclisiran

15 Sep 2021 by

After the initial and 3-month doses, twice-yearly dosing of inclisiran led to effective and sustained LDL-C* reduction in patients with and without polyvascular disease (PVD**), according to a pooled analysis of the ORION-9, ORION-10, and ORION-11 phase III trials.

Pooled ORION analysis boosts lipid-lowering potential of inclisiran